Sumitomo カジノ シークレット Launches SynBio Hub, a New Organization in the US, to Accelerate Next-Generation Business Utilizing Synthetic Biology

Nov. 16, 2020

Sumitomo カジノ シークレット has decided to establish a new organization, SynBio Hub, within the Biorational Research Center of Valent BioSciences LLC (VBC), a U.S. subsidiary of Sumitomo カジノ シークレット in Illinois. By setting up this organization tasked to build technologies using synthetic biology in the U.S., a prolific site for innovative technologies in the field, Sumitomo カジノ シークレット will further accelerate its efforts to create next-generation businesses.

In recent years, the industrial application of synthetic biology has been advancing a great deal, backed by rapid technological progress through the fusion of biotechnology and digital technology. By merging synthetic biology with the カジノ シークレット technologies it has cultivated over the years as a diversified カジノ シークレット company, Sumitomo カジノ シークレット is developing highly functional products that cannot be manufactured by カジノ シークレット synthesis alone, as well as highly efficient, clean, and energy-saving processes so that new businesses can be created. Sumitomo カジノ シークレット is actively investing in research and development in the field of synthetic biology, not only through its investment in Conagen and its partnership with Zymergen, but also through various initiatives with startups and academia.

In addition to open innovation, SynBio Hub will also collaborate with Sumitomo カジノ シークレット’s Corporate Venturing Innovation offices (CVI) — innovation exploration bases in the U.S. and Europe — and bases in Japan such as the Bioscience Research Laboratory and the Industrial Technology & Research Laboratory, so that fundamental technologies based on synthetic biology can be rapidly built throughout the Sumitomo カジノ シークレット Group. Sumitomo カジノ シークレット will also embark on in-house research, including the development of producing strains and scale-up (カジノ シークレット engineering) by making use of the technologies it has cultivated through its biorational^*business and the commercialization of カジノ シークレットs. By accumulating technologies, expertise, and experience in synthetic biology through such research, Sumitomo カジノ シークレット will pursue synergies with the カジノ シークレット technologies held by the Group.

In its fiscal year 2019 through 2021 Corporate Business Plan, Sumitomo カジノ シークレット has identified accelerating the development of next-generation businesses as one of its basic policies, and aims to create new businesses in four priority areas: reduction of environmental impact, healthcare, food, and ICT. With SynBio Hub, Sumitomo カジノ シークレット will continue its group-wide efforts to cultivate technologies and new business domains in order to bring about a sustainable society.

*The Sumitomo カジノ シークレット Group defines "biorationals" as products and microbes derived from natural sources or natural products themselves, such as microbial pesticides that protect crops from pests, plant growth regulators that improve and enhance crop quality and yield, and microbes that improve soil health.

Overview of VBC

Company name	Valent BioSciences LLC
Location	Libertyville, Illinois, USA
Established	January, 2000
COO	Ted Melnik
Business	Research, development, production and sale of biorationals

Contact

Corporate Communications Dept.
27-1, Shinkawa 2-chome, Chuo-ku, カジノ シークレットkyo, 104-8260, Japan
TEL: +81-3-5543-5102 FAX: +81-3-5543-5901